The immunopathology of intraocular tumour rejection
- PMID: 2070879
- DOI: 10.1038/eye.1991.33
The immunopathology of intraocular tumour rejection
Abstract
The immunopathology of intraocular tumour rejection was studied using two transplantable tumours in mice. UV5C25 fibrosarcoma and P91 mastocytoma express tumour specific antigens that elicit strong systemic T cell-mediated immune responses following intracameral transplantation. Although both tumours underwent immunological rejection, the immunopathological sequelae of tumour rejection differed markedly. P91 tumour rejection was accompanied by bulk ischaemic necrosis, microvascular damage, and extensive damage to innocent bystander cells. A large body of experimental evidence indicated that this ischaemic necrotic pattern of intraocular tumour rejection was the result of a delayed-type hypersensitivity (DTH) effector mechanism. By contrast, intraocular UV5C25 tumour rejection occurred by piecemeal necrosis and did not culminate in injury to juxtaposed normal host tissues. The results of in vitro and in vivo experiments strongly indicated a role for cytotoxic T lymphocyte (CTL) mediated mechanisms in the piecemeal necrotic pattern of tumour rejection. Collectively, the results indicated that although tumour bearing hosts possessed both CTL and DTH effector mechanisms, only one form of T cell-mediated immunity prevailed within the intraocular milieu.
Similar articles
-
Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.J Immunol. 1987 Jun 15;138(12):4515-23. J Immunol. 1987. PMID: 3108394
-
Spontaneous immune rejection of intraocular tumors in mice.Invest Ophthalmol Vis Sci. 1985 Jun;26(6):877-84. Invest Ophthalmol Vis Sci. 1985. PMID: 3924853
-
In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.Immunology. 1991 Sep;74(1):153-9. Immunology. 1991. PMID: 1937568 Free PMC article.
-
Immunoregulation of intraocular tumours.Eye (Lond). 1997;11 ( Pt 2):249-54. doi: 10.1038/eye.1997.60. Eye (Lond). 1997. PMID: 9349421 Review.
-
Identification of tumour rejection antigens recognized by T lymphocytes.Cancer Surv. 1992;13:23-37. Cancer Surv. 1992. PMID: 1423324 Review.
Cited by
-
Role of NKT cells in anterior chamber-associated immune deviation.Expert Rev Clin Immunol. 2009 Mar;5(2):137-144. doi: 10.1586/1744666X.5.2.137. Expert Rev Clin Immunol. 2009. PMID: 20046994 Free PMC article.
-
The privileged immunity of immune privileged organs: the case of the eye.Front Immunol. 2012 Sep 21;3:296. doi: 10.3389/fimmu.2012.00296. eCollection 2012. Front Immunol. 2012. PMID: 23049533 Free PMC article.
-
Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.Cancer Res. 2011 Apr 1;71(7):2445-54. doi: 10.1158/0008-5472.CAN-10-2628. Epub 2011 Feb 9. Cancer Res. 2011. PMID: 21307132 Free PMC article.
-
IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.J Immunol. 2011 Oct 15;187(8):4219-28. doi: 10.4049/jimmunol.1100826. Epub 2011 Sep 14. J Immunol. 2011. PMID: 21918192 Free PMC article.
-
CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.Immunology. 2008 Mar;123(3):367-77. doi: 10.1111/j.1365-2567.2007.02700.x. Epub 2007 Oct 17. Immunology. 2008. PMID: 17944931 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical